Background: The preventive effect of allergen immunotherapy (AIT) on allergy and
| INTRODUCTION
Allergen immunotherapy (AIT) is the only causative therapeutic strategy available and has been proven to reduce symptoms and medication scores. 1 In analogy to promising primary 2, 3 and secondary 4 preventive approaches in food allergy, a few studies tried to implement a preventive AIT (pAIT) approach for sublingual AIT to environmental allergens, such as House Dust Mite (HDM). [5] [6] [7] HDM is the most important perennial allergen and is highly associated with asthma development. 8 Preventive AIT is of special interest since prospective and retrospective analysis of AIT studies suggested an impact on the atopic march. [9] [10] [11] A recent meta-analysis suggested a significant shortterm reduction of asthma development in patients with allergic rhinitis treated with AIT. 12 Two placebo-controlled trials were performed to assess prevention of onset of allergy with sublingual AIT. 6, 7 The first trial focused on safety, feasibility, and immunological modulation. It demonstrated that pAIT in 2-5-year-old children is safe. It also reported the induction of regulatory mechanisms such as an increase in allergen-specific IgG and the suppression of allergen-specific T-cell proliferation in an IL-10-and TGF-β-dependent manner. The second, larger study assessed the benefit of a 12-month HDM pAIT in highrisk, non-sensitized children starting in the first year of life. Although the trial was not able to demonstrate a reduction in the number of HDM sensitizations or HDM allergy, there was a significant reduction of sensitization to allergens other than HDM in the treatment group.
Allergic asthma often occurs at the end of a sequence of events called the atopic march, which is the result of an immunological dysregulation favoring Th2 responses early in life. It is characterized by progressive sensitization to multiple allergens and an increased IgE epitope diversity over time. It remains to be clarified whether early interventions such as pAIT interfere with allergy development at a molecular level by suppressing epitope spreading. 13 This study takes advantage of a prospective placebo-controlled pAIT trial and focuses on how pAIT affects epitope spreading and the diversity of blocking antibodies by applying novel high-resolution peptide arrays that allow us to investigate the complete linear epitope spectrum of Der p and Der f.
| METHODS

| High-density peptide arrays
In an initial experimental approach, a 1-million, high-resolution, highdensity peptide array was conducted, which screened for IgG-, IgG4- Peptides from the whole Der f proteome were spotted a single time.
Serving as negative control peptides, the library included 38 423
peptides from HDM-unrelated proteins, specifically 148 snake venom toxins. 15 From previously conducted peptide microarray experiments, 437 peptides were selected as positive controls and were randomly distributed on the array in 10 replicates. Peptide synthesis was performed as described previously 16 by in-situ photolithographic synthesis in a Roche-NimbleGen Maskless Array Synthesizer using an amino-functionalized substrate carrying a photosensitive protection group. The total number of peptides on the screening array-denoted 1M array-was 947 425. Plasma from three groups, HDM-non-sensitized/non-allergic, HDM-sensitized/non-allergic, and HDM-allergic children, was used to pre-select for IgG-, IgG4-and IgE-binding peptides.
G R A P H I C A L A B S T R A C T
Preventive sublingual immunotherapy with house dust mite (HDM) extract increases IgG antibody diversity. It prevents IgE repertoire expansion to HDM proteins in pre-school children. IgG-IgE overlap suggestive for an increase in blocking antibodies diversity takes place during pAIT.
Based on the binding characteristics of the initial experiment, the second high-density peptide array (also referred as 172k peptide array in the following sections) with 54 785 unique peptides from the Der f proteome, 1509 unique peptides from already described Der f and Der p allergens, and 4493 snake venom toxin peptides (negative control peptides) was designed with all peptides synthesized in duplicates. To investigate dynamics of epitope recognition during pAIT, plasma from 9 pAIT and 10 placebo-treated children were analyzed pre-treatment, at 12 and at 24 months of treatment.
| Study population
As mentioned in the section above, for the initial peptide selection process, sera from three distinct patient groups were used as fol- Those three clinically different patients group allowed us to define the peptides recognized by clinically different groups.
For the 172K array, 9 out of the 11 HDM pAIT-treated and 10 of the 12 placebo-treated children from the preventive sublingual AIT study, all of them sensitized to HDM but without symptoms, were included. Summary of patients′ characteristics such as age, gender, allergy family history (defined by known allergies or atopic disease of the parents) is shown in Table 1 . The selection was based on the availability of plasma samples from all three visits (0, 12, and 24 m). The study design of the-pAIT trial has been described in detail recently. and/or specific IgE to Der p) and 2-5 years of age ( Table 1) . None of them reported any allergen-related symptoms or was on persistent treatment with inhalant steroids for upper and lower airways or topical steroids because of atopic dermatitis. The treatment consisted of drops applied daily under the tongue and divided into two phases: a dose-escalation and a maintenance phase according to the product information. body. In total, three different data sets were generated (IgE, IgG, and IgG4). In the IgG4 data set, data from two patients of each group had to be excluded since they did not meet the quality control requirements.
For the screening experiment, three pools consisting of three serum samples per pool for allergic, sensitized non-allergic and nonsensitized, non-allergic individuals were measured (ie, three samples per group harboring immunoglobulin diversity of a total of nine patients totaling sera from 27 well-characterized individuals).
| Data analysis
Data pre-processing was comparable for the 1M and the 172K highdensity peptide arrays. A sample-wise standardization of the 3 | RESULTS
| Preventive allergen immunotherapy with HDM extract results in a significantly broader IgG repertoire
Plasma samples from the randomized double-blind placebo-controlled pAIT trial were evaluated for IgE, IgG, and IgG4 binding in a 172K
high-density, high-resolution peptide array, containing 16-mer peptides derived from all published HDM allergens (Der f and Der p) (Figure 1 ).
At baseline, IgG diversity was well matched between placebo and pAIT. The diversity of IgG-binding peptides to HDM allergens was significantly higher in the pAIT after 2 years of treatment compared to the placebo. Allergen-specific IgG4 is considered crucial for blocking of the allergen-specific responses and one of the key protective mechanisms of AIT. There was mildly increased IgG4 diversity at baseline in the pAIT group (P = 0.12), which was not significant. In line with allergen-specific IgG data, IgG4 epitope diversity was higher in the pAIT group after 24 months of treatment compared to the placebo-treated patients ( Figure 2 ). There was no increase in IgE repertoire diversity to Der p and Der f allergens in case of pAIT. However, the placebo group displayed a trend toward an overall increase over time displaying significance 12 months post inclusion ( Figure 2 ).
In addition, we analyzed the overlap in peptide recognition between IgE and IgG including IgG4. Preventive AIT-treated patients showed after 24 months of treatment significantly more IgG specificity to preexisting IgE HDM allergen epitopes mapped at baseline compared to the placebo group (median 18 vs 40 overlapping epitopes, Figure S1 ).
| Epitope binding characteristics to the Der f proteome
The recently published genome of Der f 14 allowed us to perform a holistic approach covering the whole proteome of Der f. This 
| Individual allergen patterns reflect overall changes
Allergen extracts used for AIT include a broad variety of allergens at different concentrations. Therefore, IgE, IgG, and IgG4 new peptide recognition frequencies were analyzed at the level of individual allergens. The extend of de novo generated epitopes per allergen was significantly higher with regard to IgG and significantly lower for IgE in the treatment group compared to the placebo-treated group. No significant differences were seen regarding delta of IgG4-recognized peptides ( Figure 4 ). IgE diversity increased in the majority of individual allergens within 24 months at preschool age when placebo was applied (P < 0.05). This epitope spreading was not observed in the pAIT group. IgG diversity increased significantly in the pAIT group during treatment (P < 0.05), whereas no increase was observed in the placebo group. IgG4 diversity at a single allergen level demonstrated significant baseline differences and displayed no differences at the endpoint (after 2 years of treatment) ( Figure S2 ).
| DISCUSSION
Allergen immunotherapy has been assumed to modify disease progression, and there is good retrospective and some prospective evidence that AIT reduces de novo sensitizations to allergens. It may further affect subsequent events such as the development of allergic asthma. 9, 10, 17, 18 However, robust prospective data as well as mechanistic data at the molecular level supporting the beneficial effects of preventive interventions are scarce. This study provides first In a previous publication that focused on the safety aspects of this trial, 7 we were able to demonstrate a TGF-beta and IL10-dependent immunomodulatory effect at a T-cell level. Moreover, the generation of blocking IgG antibodies against Der p1 and Der p2 was demonstrated in a quantitative manner. These outcomes are well known in therapeutic application of AIT. However, the changes at a molecular level with regard to epitope diversity remain unclear.
Moreover, a key aspect of this project is to delineate dynamics of diversity.
The longest preventive sublingual pAIT trial that was performed in very young children (<12 months) 6 could not show prevention of de novo sensitization to HDM in a high-risk population. But there was evidence that the co-sensitizations were significantly reduced in the treatment group. It is unclear whether the observed IgE responses in the treatment group will result in clinical symptoms or rather reflect IgE responses in a high-risk group upon exposure without direct clinical implications. Follow-up data will bring more information about regarding clinics.
It is known that one of the characteristics of the atopic march is the development of IgE antibodies to new epitopes and the spreading of sensitization to new allergenic proteins from other sources. 19 Evidence for a linkage of epitope diversity and disease severity has also been provided for milk and peanut allergy. [20] [21] [22] Therefore, we would expect an increase in IgE diversity over time in the placebo group reflecting the natural course in a high-risk group. In fact, we saw a significant increase in diversity in the placebo group within the first 12 months after inclusion. Interestingly, this progression was modified by pAIT. Beyond a surrogate analysis including all known allergens, we also investigated whether dynamics of epitope recognition are different when looking at HDM allergens individually. In fact, IgE diversity increased in the placebo group significantly in the majority of Der p and Der f allergens, whereas that did not happen in the pAIT-treated group. On the contrary, a statistically significant increase in IgG diversity was observed in the treatment group.
In addition to known allergens, we chose a new approach by synthesising the whole proteome of Der f. The intention was to include still unknown linear epitopes from the HDM itself. This approach harbors the potential to identify new allergens on the one hand but more importantly allows for the assessment of potential bystander effects. As anticipated, the changes in the proteomederived peptide pool were not as pronounced as in the allergen pool.
Nevertheless, IgE binding was significantly reduced at 12 months of treatment and a trend toward an increase in IgG diversity was observed. This adds to the body of evidence discussed above and suggests a beneficial immunomodifying effect of pAIT.
Regarding the clinical effects of preventive AIT on asthma development, the recently published GAP trial on sublingual grass AIT in allergic rhinitis patients did not meet the primary endpoint. However, it provided evidence that AIT modifies grass pollen allergy by reducing asthma symptoms and medication scores with a more pronounced effect in the 2-year follow-up period. 32 Moreover, the increase in allergen-specific IgE was significantly lower in the treatment group. Interestingly, the younger the children were, the ; placebo n = 10), IgG (pAIT n = 9; placebo n = 10) and IgG4 (pAIT n = 7; placebo n = 8) antibodies. pAIT, preventive allergen immunotherapy group stronger the beneficial effect on the prevention of asthma symptoms. 10 Patients in our study are even younger and represent an earlier stage of the disease. Although our study was not powered to assess clinical efficacy, we checked whether there was any evidence suggestive for an impact of pAIT on asthma development over a longer period of time. Four-year follow-up data showed a lower asthma incidence (1/9 treatment vs 3/10 placebo; data not shown).
In conclusion, the use of high-density peptide arrays revealed that HDM pAIT in children 2-5 years of age shows molecular evidence for immunomodulation by influencing epitope recognition and therefore interfering in the natural course of atopic march. Therefore, this study contributes to a better understanding of pAIT mechanisms of action at a B-cell level. Further research is desired and essential to evaluate and understand the secondary prevention of HDM allergy and asthma.
CONF LICTS OF INTEREST
The authors declare that they have no conflicts of interest. T.E. designed the study, contributed to manuscript′s generation and was involved in data analysis and supervised the whole project.
AUTHOR CONTRIBU TI ONS
O R C I D
Marta
Ponce https://orcid.org/0000-0002-8730-5987
Thomas Eiwegger https://orcid.org/0000-0002-2914-7829
